Futibatinib, also known as 福巴替尼 in Chinese and LYTGOBI as another common name, is a second-generation FGFR-targeted drug used primarily for treating bile duct cancer that has developed resistance to first-generation FGFR inhibitors. The cost of this medication can vary significantly depending on factors such as the region, the specific formulation, and whether it is covered by insurance. In this article, we will explore the price of Futibatinib and provide some essential information about its usage and precautions.

Futibatinib Price Overview

Futibatinib is a relatively new drug that has gained approval in several countries, including the United States, Japan, and the European Union. As of 2023, the approximate price of Futibatinib is around $1,200 per box. However, this price can fluctuate based on various factors:

Factors Affecting Price

Region: The cost of Futibatinib can differ from one country to another. For example, in the United States, the price might be higher compared to other regions where healthcare costs are generally lower.

Specification: The price can also vary depending on the specification of the medication. Typically, a box of Futibatinib contains 35 tablets, each with a 4mg dosage. If a different specification is required, the price may change accordingly.

Manufacturer: Different manufacturers may set different prices for their versions of Futibatinib. For instance, the original drug produced by Taiho Oncology (日本太浩制药) might have a different price compared to generic versions produced by other pharmaceutical companies.

Insurance Coverage

In many countries, Futibatinib is not yet covered by national health insurance programs. This means that patients may need to pay out-of-pocket for the medication, which can be a significant financial burden. It is advisable to check with local healthcare providers or insurance companies to understand the coverage options available.

For patients who do not have insurance coverage, some pharmaceutical companies offer patient assistance programs that can help reduce the cost. These programs may provide discounts or even free medication to eligible patients.

Using Futibatinib Safely

While Futibatinib is an effective treatment for certain types of cancer, it is important to use it safely and follow the prescribed guidelines to minimize potential side effects and maximize its benefits.

Dosage and Administration

The recommended dose of Futibatinib is 20mg (five 4mg tablets) taken orally once daily. Patients should take the medication at approximately the same time each day, either with or without food. It is important to swallow the tablets whole and not to crush, chew, split, or dissolve them.

If a dose is missed by more than 12 hours or if vomiting occurs after taking the medication, patients should skip the missed dose and resume the regular dosing schedule. It is crucial to follow the healthcare provider's instructions regarding dosage adjustments or discontinuation of the medication.

Monitoring and Side Effects

Futibatinib can cause several side effects, some of which may require close monitoring:

Ocular Toxicity: One of the notable side effects of Futibatinib is retinal pigment epithelial detachment (RPED), which can lead to symptoms such as blurred vision. Patients should undergo a comprehensive eye examination, including optical coherence tomography (OCT), before starting treatment and regularly during the first six months. Subsequent examinations should be conducted every three months. Any visual symptoms should prompt immediate referral to an ophthalmologist.

Hyperphosphatemia and Soft Tissue Mineralization: Futibatinib can cause hyperphosphatemia, leading to conditions such as soft tissue mineralization, calcification, and vascular calcification. Regular monitoring of phosphate levels is essential. If serum phosphate levels exceed 5.5 mg/dL, patients should start a low-phosphate diet and receive phosphate-lowering therapy. For levels above 7 mg/dL, the dosage of Futibatinib may need to be reduced, interrupted, or permanently discontinued.

Special Populations

Certain groups of patients may require special considerations when using Futibatinib:

Pregnancy: Based on animal studies, Futibatinib can cause fetal harm or miscarriage. There is no data available on the use of Futibatinib in pregnant women. Women of childbearing potential should be informed of the potential risks to the fetus and advised to use effective contraception during treatment and for one week after the last dose.

Breastfeeding: There is no data on the presence of Futibatinib or its metabolites in breast milk. Due to the potential for serious adverse reactions in breastfed infants, women are advised not to breastfeed during treatment and for one week after the last dose.

Elderly Patients: In clinical trials, approximately 22% of patients treated with Futibatinib were 65 years or older. No significant differences in safety or efficacy were observed between older and younger adult patients. However, elderly patients may be more susceptible to certain side effects, so close monitoring is recommended.

By following these guidelines and working closely with healthcare providers, patients can use Futibatinib safely and effectively to manage their condition.